Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer

Oncology

Volumn 80, Issue 5-6, 2011, Pages 341-349

  Vargo, John A ^a,b   Beriwal, Sushil ^a   Ahrendt, Gretchen M ^a   Soran, Atilla ^a   Johnson, Ronald R ^a   McGuire, Kandace ^a   Bhargava, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b West Virginia University School of Medicine Charleston   (United States)

Author keywords

Adjuvant chest wall radiation; Breast cancer molecular class; Immunohistochemical surrogate markers; Locoregional failure; Neoadjuvant chemotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79960677027     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000330203     Document Type: Article

References (38)

1. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785. (Pubitemid 351264391)
2. Mauri D, Pavlidis N, Ioannidis JPA: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 188-194. (Pubitemid 40277368)
3. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF: Neoadjuvant therapy for breast cancer. J Surg Oncol 2010; 101: 283-291.
4. Mieog JS, van der Hage JA, van de Velde CJ: Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007; 94: 1189-1200. (Pubitemid 47584766)
5. Wapnir IL, Anderson SJ, Mamounas EP, et al: Prognosis after ipsilateral breast tumor recurrence and locoregional recurrence in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trails. J Clin Oncol 2006; 24: 2028-2037. (Pubitemid 46622111)
6. Andrews JZ, Njoku V, Bowling M, Weed D, Goulet R, Sledge W: Local recurrence after neoadjuvant chemotherapy for breast cancer: Implications for partial breast irradiation (abstract 302). ASCO Breast Cancer Symp, San Francisco, 2009.
7. Huang EH, Tucker SL, Strom EA, et al: Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004; 22: 4691-4699.
8. Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 366: 2087-2106. (Pubitemid 41797643)
9. Haffty BG, Goyal S: Molecular subtyping of early-stage breast cancer: Implications for radiation therapy. Int J Radiat Oncol Biol Phys 2010; 77: 1293-1295.
10. Mamounas EP, Tang G, Fisher B, et al: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptorpositive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010; 28: 1677-1683.
11. Huang EH, Tucker SL, Strom EA, et al: Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 351-357. (Pubitemid 40704449)
12. Albert JM, Gonzalez-Angulo AM, Guray M, et al: Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1296-1302.
13. Haffty BG, Brown F, Carter D, Flynn S: Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. Int J Radiat Oncol Biol Phys 1996; 35: 751-757. (Pubitemid 26251130)
14. Cebrecos I, Cordoba O, Deu J, Xercavins J, Rubio IT: Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy? Eur J Surg Oncol 2010; 36: 528-534.
15. Harris EE, Hwang WT, Lee EA, et al: The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conservation therapy. Breast J 2006; 12: 431-436. (Pubitemid 44337435)
16. Freedman GM, Anderson PR, Li T, Nicolaou N: Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 2009; 115: 946-951.
17. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer. J Clin Oncol 2006; 24: 5652-5657. (Pubitemid 46631305)
18. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-2378.
19. Bhargava R, Dabbs DJ: Luminal B breast tumors are not HER2 positive. Breast Cancer Res 2008; 10: 404.
20. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormone therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
21. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
22. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334. (Pubitemid 46698581)
23. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502. (Pubitemid 43854964)
24. Nielson TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characteristics of the basal-like subtype of invasive breast carcinoma. Clin Caner Res 2004; 10: 5367-5374. (Pubitemid 39100473)
25. Bhargava R, Beriwal S, Dabbs DJ, et al: Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer 2010; 116: 1431-1439.
26. Dent R, Trudeau M, Pritchard KI, et al: Triple- negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434. (Pubitemid 47219710)
27. Puglisi F: Locoregional recurrence of triplenegative breast cancer after breast-conservation surgery and radiation. Cancer 2010; 116: 538.
28. Huang EH, Strom EA, Perkins GH, et al: Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 2006; 66: 352-357. (Pubitemid 44332738)
29. Mannino M, Yarnold JR: Local relapse rates are falling after breast conservation surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld? Radiother Oncol 2009; 90: 14-22.
30. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. (Pubitemid 32878711)
31. Cheang MC, Chai SK, Voduk D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
32. Millar EK, Graham PH, O'Toole SA, et al: Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009; 27: 4701-4708.
33. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469. (Pubitemid 29075229)
34. Chollet P, Amat S, Cure H, et al: Prognostic significance of a complete pathologic response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86: 1041-1046. (Pubitemid 34441058)
35. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685. (Pubitemid 28363030)
36. Thomas E, Holmes FA, Smith TL, et al: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicinbased regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004; 22: 2294-2302. (Pubitemid 41115385)
37. Alvarez RH, Booser DJ, Cristofanilli M, et al: Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphomide, methotrexate, and 5-fluorouracil based on clinical and pathological response in patients with stage IIB to III breast cancer: Long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 2010; 116: 1210-1217.
38. Von Minchwitz G, Kummel S, Vogel P, et al: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-551.